Oncology Research Digest H1 2014

August 14, 2014 : Bharat Book Bureau presents the new report, on " Oncology Research Digest H1 2014”. The Asia Pacific region looks the most attractive geography in terms of potential, however the Indian and Chinese markets remain hindered by local market factors.

The Oncology Research Digest is a digest of all the most important research in the oncology market each quarter, and available as an annual subscription. It covers areas such as biosimilars, novel immunotherapies, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, ovarian cancer and drugs such as Rituxan, Avastin, Herceptin, Traceva, Xeloda, Gleevec, Revlimid, Alimta, Velcade. It is gathered from over 50 sources including associations, consultants, market intelligence companies, investment banks, and industry participants.

Updated quarterly, the Digest allows you to:

• Quickly update yourself on the latest research findings, gathered and organised for you.

• Get our Expert Analysts’ perspectives on the latest research.

• Link through to the original research to review or purchase.

Oncology Research Digest H1 2014 finds that the cancer market is successfully adapting to challenges. Patent expires and payer pressures have led to relatively slow growth in the cancer market in the last five years, and this will continue to be a feature. However the launch of new drugs for the treatment of various types of cancers including lung, blood and pancreatic cancer are expected to drive growth. New drugs will also drive global markets for Non-Small Cell Lung Cancer, Anti- Cancer and Lymphocytic Cancer. These new products will change the shape of the market, with players such as Johnson and Johnson coming to the fore.

In terms of geographies, the US market continues to lead with the prices of cancer drugs and treatment costs increasing due to the shift in the US healthcare system. The Asia Pacific region looks the most attractive geography in terms of potential, however the...